NCT06231550View on ClinicalTrials.gov

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 18, 2025

Study Completion Date

March 18, 2025

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

FC084CSA tablets

"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

FindCure Biosciences (ZhongShan) Co., Ltd.

INDUSTRY